Characteristics	LR			IR/HR		
	Program1	Program2	P value	Program1	Program2	P value
Age(years)	4.2((3-6)	5(3.6-9.3)	0.146	5.8(3.1-9.5)	7.5(3.5-11.7)	0.039
Sex			0.206			0.001
female	53 (34%)	13(46.4%)		109(43.8%)	21(23.3%)	
male	103(60%)	15(53.6%)		140(56.2%)	69(76.7%)	
Immunophenotype			-			0.257
B-ALL	156	28		212(85.1%)	72(80%)	
T-ALL	-	-		37(14.9%)	18(20%)	
Actual MTX dose(g/m^2)	2.4(1.92-2.4)	3(3-3)	<0.001	3.6(2.56-4)	4.16(3.5-5.0)	<0.001
Actual MTX infusion rate	0.8(0.64-0.8)	1(1-1)	<0.001	0.72(0.51-0.8)	0.83(0.7-1)	<0.001
Leucovorin dose(mg/m^2)	75(75-135)	75(75-97.5)	0.371	75(75-180)	82.5(75-243.7	0.023
Days ANC < 1.0*10^9/L			0.527			0.003
no	72(46.2%)	10(35.7%)		91(36.5%)	26(28.9%)	
1-7days	56(35.9%)	13(46.4%)		115(46.2%)	33(36.7%)	
> 7days	28(17.9%)	5(17.9%)		43(17.3%)	31(34.4%)	
Days of chemotherapy delay			0.35			0.384
No	145(92.9%)	28(100%)		242(97.2%)	88(97.8%)	
Yes	11(7.1%)	0		7(2.8%)	2(2.2%)	
Serum potassium			<0.001			<0.001
Normal	142(91%)	18(64.3%)		220(88.4%)	57(63.3%)	
Hypokalemia (< 3.5) or hyperkalemia(> 5.2)	14(9%)	10(35.7%)		29(11.6%)	33(36.6%)	

Toxicity			0.232			0.394
G0	91(58.3%)	21(75%)		129(51.8%)	41(45.6%)	
Grade1/Grade2	43(27.6%)	4(14.3%)		82(32.9%)	30(33.3%)	
Grade3/Grade4	22(14.1%)	3(10.7%)		38(15.3%)	19(21.1%)	

*The values are expressed as number (%) or median (p25-p75)

TABLE 4 Basic demographic information, treatment data and toxicity of two MTX dose adjustment programs.